[go: up one dir, main page]

MX2008002275A - Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. - Google Patents

Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Info

Publication number
MX2008002275A
MX2008002275A MX2008002275A MX2008002275A MX2008002275A MX 2008002275 A MX2008002275 A MX 2008002275A MX 2008002275 A MX2008002275 A MX 2008002275A MX 2008002275 A MX2008002275 A MX 2008002275A MX 2008002275 A MX2008002275 A MX 2008002275A
Authority
MX
Mexico
Prior art keywords
hypnotic agent
acting hypnotic
combination
short
long
Prior art date
Application number
MX2008002275A
Other languages
English (en)
Inventor
Alain Cuine
Michel Decobert
Dominique Francon
Henry Saunal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2008002275A publication Critical patent/MX2008002275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a la asociacion de un agente hipnotico de duracion de accion corta elegida entre un modulador de los receptores GABA-A, una benzodiazepina, las fenotiazinas, un derivados de la melatonina un agonistas de los receptores de la melatonina y de un agente hipnotico de duracion de accion larga elegida entre un modulador de los receptores GABA-A, una benzodiazepina, un antagonista de los receptores 5HT2A, un modulador de los iones calcio para tratar los trastornos de sueno. La invencion se refiere igualmente alas formulaciones galenicas que encierran esta asociacion.
MX2008002275A 2005-08-19 2006-07-27 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. MX2008002275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508643A FR2889811B1 (fr) 2005-08-19 2005-08-19 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
PCT/FR2006/001830 WO2007020337A1 (fr) 2005-08-19 2006-07-27 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique

Publications (1)

Publication Number Publication Date
MX2008002275A true MX2008002275A (es) 2008-03-27

Family

ID=36273351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002275A MX2008002275A (es) 2005-08-19 2006-07-27 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Country Status (25)

Country Link
US (2) US20080181943A1 (es)
EP (1) EP1919473B1 (es)
JP (1) JP5215851B2 (es)
KR (1) KR20080039909A (es)
CN (1) CN101267819B (es)
AR (1) AR055123A1 (es)
AU (1) AU2006281334B2 (es)
BR (1) BRPI0614792A2 (es)
CA (1) CA2618212C (es)
CR (1) CR9695A (es)
EA (1) EA014294B1 (es)
EC (1) ECSP088131A (es)
FR (1) FR2889811B1 (es)
HN (1) HN2008000278A (es)
IL (1) IL188823A0 (es)
MA (1) MA29766B1 (es)
MX (1) MX2008002275A (es)
NO (1) NO20081250L (es)
NZ (1) NZ565880A (es)
SG (1) SG165316A1 (es)
TN (1) TNSN08027A1 (es)
TW (1) TW200738238A (es)
UA (1) UA93209C2 (es)
WO (1) WO2007020337A1 (es)
ZA (1) ZA200800968B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
US20120108669A1 (en) * 2008-11-13 2012-05-03 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP5726766B2 (ja) 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2255807A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
WO2012109695A1 (en) * 2011-02-16 2012-08-23 Casal Y Galzov Ramon Ernesto Drug compositions for the treatment of insomnia
US9700548B2 (en) 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
CN102579383A (zh) * 2012-04-09 2012-07-18 南京正科制药有限公司 右佐匹克隆缓释片
PT3102189T (pt) * 2014-02-06 2019-12-11 Bo Chen Lan Composição e método para melhorar o sono
CN108289849A (zh) 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
CN105596313B (zh) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 一种具有反向药理功能的用于治疗失眠的胶囊制剂
CN105997958B (zh) * 2016-07-12 2019-03-26 中国人民解放军白求恩医务士官学校 一种口腔外用制剂及其制备方法
RS61024B1 (sr) * 2016-10-31 2020-12-31 Neurim Pharma 1991 Mini-tablete melatonina i postupak za njihovu proizvodnju
JP7053665B2 (ja) * 2016-12-30 2022-04-12 南京明徳新薬研発有限公司 Ｅｇｆｒ阻害としてのキナゾリン系化合物
CN118384147A (zh) 2018-01-30 2024-07-26 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3129270A1 (en) * 2019-02-08 2020-08-13 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
CN115919806A (zh) * 2022-12-22 2023-04-07 南京乐韬生物科技有限公司 一种gaba缓释胶囊的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
DK1691811T3 (da) * 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
CA2614244A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
EP1937265A2 (en) * 2005-08-19 2008-07-02 Aventis Pharmaceuticals Inc. Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
SG140147A1 (en) * 2005-08-19 2008-03-28 Aventis Pharma Inc Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof

Also Published As

Publication number Publication date
FR2889811A1 (fr) 2007-02-23
KR20080039909A (ko) 2008-05-07
EP1919473B1 (fr) 2012-12-05
JP5215851B2 (ja) 2013-06-19
HK1124541A1 (en) 2009-07-17
AU2006281334B2 (en) 2012-10-18
ECSP088131A (es) 2008-02-20
IL188823A0 (en) 2008-12-29
EA014294B1 (ru) 2010-10-29
UA93209C2 (ru) 2011-01-25
AU2006281334A1 (en) 2007-02-22
CA2618212A1 (fr) 2007-02-22
CA2618212C (fr) 2014-03-25
FR2889811B1 (fr) 2009-10-09
WO2007020337A1 (fr) 2007-02-22
CN101267819B (zh) 2012-05-30
JP2009504713A (ja) 2009-02-05
EA200800618A1 (ru) 2008-06-30
AR055123A1 (es) 2007-08-08
ZA200800968B (en) 2009-04-29
HN2008000278A (es) 2011-03-30
MA29766B1 (fr) 2008-09-01
US20080181943A1 (en) 2008-07-31
NZ565880A (en) 2011-07-29
CR9695A (es) 2008-02-20
SG165316A1 (en) 2010-10-28
TNSN08027A1 (en) 2009-07-14
TW200738238A (en) 2007-10-16
CN101267819A (zh) 2008-09-17
US20100291204A1 (en) 2010-11-18
NO20081250L (no) 2008-05-13
EP1919473A1 (fr) 2008-05-14
BRPI0614792A2 (pt) 2011-04-12

Similar Documents

Publication Publication Date Title
TNSN08027A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
SV2005002148A (es) &#34;compuestos moduladores de la actividad c-kit y usos de los mismos&#34;
AP1542A (en) Glucocorticoid receptor modulators.
BRPI0418092A (pt) combinação terapêutica para melhora cognitiva e transtornos psicóticos
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
BR0104834A (pt) Moduladores de receptores de glucocorticóides
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
ATE327974T1 (de) Modulatoren des glucocorticoid-rezeptors
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
HRP20041014B1 (hr) Novi spojevi kao modulatori opioidnog receptora
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
IL183339A0 (en) Pyrolidine-2-one derivatives and pharmaceutical compositions containing them
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
AU2003288858A1 (en) Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases

Legal Events

Date Code Title Description
FG Grant or registration